Glenmark Pharmaceuticals Limited has uploaded the audio recording of its first quarter fiscal year 2027 earnings call to its official website. The conference call took place on August 3, 2026, providing investors with direct access to management commentary regarding the company’s financial performance for the period. This disclosure ensures transparency and allows stakeholders to review the detailed discussion on operational and financial metrics presented during the event.

The company submitted this information to the National Stock Exchange of India Limited and BSE Limited in compliance with regulatory requirements. Specifically, the disclosure was made pursuant to Regulation 30 and Regulation 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These regulations mandate timely dissemination of material information to listed entities’ shareholders and the broader market.

Disciplinary Compliance Details

Glenmark Pharmaceuticals Limited confirmed that the audio file is hosted at a specific URL on its corporate domain. The reference number for this communication is 40/26-27. The submission was digitally signed by Rashmi Khandelwal, the Company Secretary & Compliance Officer, on August 3, 2026. Her ACS number is 28839. The company’s registered office is located in Mumbai, and it operates under CIN L24299MH1977PLC019982.

Accessing the Recording

Investors and analysts can access the recording directly via the link provided in the exchange filing. The file is named "Q1 FY27 Earnings Call recording.mp3" and is stored in the Financials/Quarterly section of the Glenmark Pharmaceuticals website. This direct access mechanism aligns with best practices for investor relations, ensuring that all market participants have equal opportunity to hear management’s perspective on the quarter’s results without delay.

Glenmark Pharmaceuticals reported a consolidated net profit of ₹4.83B for the quarter ended June 30, 2026 (Q1FY27), marking a sharp year-on-year increase from ₹469M in the corresponding period of FY26. The Mumbai-based pharmaceutical company's total revenue from operations rose to ₹40.2B in Q1FY27, compared to ₹32.6B in Q1FY26, reflecting broad-based growth across key markets. This strong bottom-line performance was primarily driven by higher net sales, improved operational efficiencies, and the absence of significant exceptional losses that impacted the prior year's comparatives, offering investors a clear signal of normalized profitability.

The Board of Directors approved the unaudited standalone and consolidated financial results on July 31, 2026, pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors Walker Chandiok & Co LLP issued an unmodified review conclusion on the results. The company also announced that its 48th Annual General Meeting will be held on September 11, 2026, with the record date for dividend entitlement set at August 31, 2026.

Financial Performance Highlights

The following table outlines the key financial metrics for Glenmark Pharmaceuticals on a consolidated basis for Q1FY27 versus Q1FY26:

Regional Revenue Breakdown

Glenmark’s growth was supported by double-digit revenue increases across all major geographies. North America emerged as the fastest-growing region, while India and Emerging Markets also delivered strong performances.

Note: North America revenue includes deferred out-licensing income recognition for ISB 2001. Net of this item, core business growth in North America was 19.8%.

Operational and Strategic Developments

During the quarter, Glenmark transferred its nebulizer brands and intellectual property portfolio to its wholly-owned subsidiary, Glenmark Healthcare Limited, for a cash consideration of ₹2.23B. This transaction was recognized as an exceptional item in the standalone financial results. In India, the formulation business outperformed the industry peer market (IPM), growing by 18.1% compared to IPM growth of 12.2%. Key brands like CANDID® and SCALPE® recorded revenue growth of over 30%.

In North America, Glenmark launched nine new products, including Methylene Blue Injection and Vancomycin Hydrochloride. The company strengthened its respiratory franchise with the first ANDA approval for Fluticasone Propionate Inhalation Aerosol, securing a Competitive Generic Therapy designation. In Europe, WINLEVI® gained traction across multiple markets, including the Nordics and Spain. Emerging Markets saw strong momentum, with Russia’s secondary sales growing by 12% and RYALTRIS® leading in allergic rhinitis treatment.

What the Numbers Show

The surge in net profit is largely attributable to both operational improvement and the absence of significant exceptional losses that impacted the prior year's comparatives. In Q1FY26, the company had recognized exceptional losses related to antitrust settlements and inventory provisions. In contrast, Q1FY27 saw no such consolidated exceptional items, allowing operating profits to flow directly to the bottom line. The EBITDA margin expansion to 19.51% from 17.78% further underscores improved cost management and a favorable revenue mix, particularly given the high-growth contribution from North America and Emerging Markets.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE935A01035/3098ab56-9349-4dd7-b5a1-07719c17f0a2.pdf